Expression of molecular markers in mediastinal nodes from resected stage I non-small-cell lung cancer (NSCLC): prognostic impact and potential role as markers of occult micrometastases

被引:41
作者
Benlloch, S. [1 ]
Galbis-Caravajal, J. M. [2 ]
Alenda, C.
Peiro, F. M.
Sanchez-Ronco, M. [3 ]
Rodriguez-Paniagua, J. M.
Baschwitz, B.
Rojas, E.
Massuti, B.
机构
[1] Hosp Gen Univ Alicante, Unidad Invest, Res Unit, Alicante 03010, Spain
[2] Hosp La Ribera, Alzira, Spain
[3] Univ Alcala de Henares, Madrid, Spain
关键词
AXILLARY LYMPH-NODES; TUMOR-CELLS; BONE-MARROW; COLORECTAL-CANCER; METASTASIS; GENE; CARCINOMA; BREAST;
D O I
10.1093/annonc/mdn538
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Occult lymph node (LN) metastases are clinically relevant and confer a worse prognosis in non-small-cell lung cancer (NSCLC) patients. Current staging methods are unable to identify patients with poor outcome. Their detection requires both a more sensitive and specific technique. We aimed to assess the role of messenger RNA expression in pathologically negative LNs (pN0) of stage I NSCLC patients as markers of occult micrometastases and to correlate the results with local or distant tumor recurrence and survival. Patients and methods: Potential molecular markers were evaluated in 344 LNs and 38 tumors by quantitative real-time RT-PCR. Only CEACAM5 and PLUNC showed high expression in lung tumor tissue and null expression in RNA from benign LNs. Results: Thirteen per cent of the LNs were positive for CEACAM5 and 16% for PLUNC. Eight of 38 NSCLC patients had positive expression in pN2 nodes by CEACAM5 and/or PLUNC and disease-free survival (P = 0.028) and overall survival time was significantly worse in these patients compared with those with negative expression (P = 0.0083). Conclusions: Quantitative real-time RT-PCR of CEACAM5 and PLUNC can estimate the presence of micrometastatic cells in LNs with greater precision than current staging method used for assessing tumor recurrence risk.
引用
收藏
页码:91 / 97
页数:7
相关论文
共 32 条
[1]  
[Anonymous], 1983, Am Rev Respir Dis, V127, P659
[2]   Lose-specific extent of systematic lymph node dissection for non-small cell lung carcinomas according to a retrospective study of metastasis and prognosis [J].
Asamura, H ;
Nakayama, H ;
Kondo, H ;
Tsuchiya, R ;
Naruke, T .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 117 (06) :1102-1111
[3]  
Ayabe Takanori, 2004, Ann Thorac Cardiovasc Surg, V10, P152
[4]   An anatomy of normal and malignant gene expression [J].
Boon, K ;
Osório, EC ;
Greenhut, SF ;
Schaefer, CF ;
Shoemaker, J ;
Polyak, K ;
Morin, PJ ;
Buetow, KH ;
Strausberg, RL ;
de Souza, SJ ;
Riggins, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (17) :11287-11292
[5]  
Coello Michael C, 2004, Clin Lung Cancer, V5, P214
[6]  
COTE RJ, 1995, ANN SURG, V222, P415
[7]   The case for early detection [J].
Etzioni, R ;
Urban, N ;
Ramsey, S ;
McIntosh, M ;
Schwartz, S ;
Reid, B ;
Radich, J ;
Anderson, G ;
Hartwell, L .
NATURE REVIEWS CANCER, 2003, 3 (04) :243-252
[8]   Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs) [J].
Ishii, H ;
Yazawa, T ;
Sato, H ;
Suzuki, T ;
Ikeda, M ;
Hayashi, Y ;
Takanashi, Y ;
Kitamura, H .
LUNG CANCER, 2004, 45 (03) :325-337
[9]  
Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO
[10]  
2-B